Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Active, not recruiting · NCT03728972 · Registry updated 2025-10-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type | Pathologic Processes, Pathological Conditions, Signs and Symptoms, disease | Active, not recruiting | Phase 2 | 2025-10-23 | NCT03728972 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hackensack Meridian Health | Hackensack | United States | 22 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | United States | 131 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | United States | 184 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | United States | 186 |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | United States | 120 |
| Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) | Commack | United States | 21 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | United States | 166 |
| Stanford University | Stanford | United States | 213 |